1-12 of 12
blinatumomab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency

Clinical Trials & Observations
Sandheeah Ramdeny, Asima Chaudhary, Austen Worth, Sara Ghorashian, Mary Slatter, Su Han Lum, Ajay Vora
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2153–2155.
https://doi.org/10.1182/bloodadvances.2021004284
Published: 2021
Journal Articles

Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab

Clinical Trials & Observations
Talha Badar, Aniko Szabo, Anjali Advani, Martha Wadleigh, Shukaib Arslan, Muhammad Ali Khan, Ibrahim Aldoss, Caitlin Siebenaller, Elizabeth Schultz, Mehrdad Hefazi, Rory M. Shallis, Ilana Yurkiewicz, Nikolai Podoltsev, Anand A. Patel, Emily Curran, Suresh Balasubramanian, Jay Yang, Ryan J. Mattison, Madelyn Burkart, Shira Dinner, Michaela Liedtke, Mark R. Litzow, Ehab Atallah
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2308–2316.
https://doi.org/10.1182/bloodadvances.2019001381
Published: 2020
Includes: Supplemental data
Journal Articles

Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia

Clinical Trials & Observations
Alessandro Rambaldi, Francoise Huguet, Pavel Zak, Paul Cannell, Qui Tran, Janet Franklin, Max S. Topp
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1518–1525.
https://doi.org/10.1182/bloodadvances.2019000874
Published: 2020
Includes: Supplemental data
Journal Articles

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy

Vinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, Asen Bagashev, Derek A. Oldridge, Jaclyn Rosenthal, John Van Arnam, Jos J. Melenhorst, Diwakar Mohan, Amanda M. DiNofia, Minjie Luo, Sindhu Cherian, Jonathan R. Fromm, Gerald Wertheim, Andrei Thomas-Tikhonenko, Michele Paessler, Carl H. June, Eline T. Luning Prak, Vijay G. Bhoj, Stephan A. Grupp, Shannon L. Maude, Susan R. Rheingold
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3539–3549.
https://doi.org/10.1182/bloodadvances.2019000692
Published: 2019
Includes: Supplemental data
Journal Articles

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Clinical Trials & Observations
Nicola Gökbuget, Hagop M. Kantarjian, Monika Brüggemann, Anthony S. Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard Heffner, Françoise Rigal-Huguet, Mark Litzow, Susan O’Brien, Gerhard Zugmaier, Shan Gao, Dirk Nagorsen, Stephen J. Forman, Max S. Topp
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3033–3037.
https://doi.org/10.1182/bloodadvances.2019000457
Published: 2019
Includes: Supplemental data
Journal Articles

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

Clinical Trials & Observations
Vera Dufner, Cyrus M. Sayehli, Manik Chatterjee, Horst D. Hummel, Götz Gelbrich, Ralf C. Bargou, Maria-Elisabeth Goebeler
Journal: Blood Advances
Blood Adv (2019) 3 (16): 2491–2498.
https://doi.org/10.1182/bloodadvances.2019000025
Published: 2019
Includes: Supplemental data
Journal Articles

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia

Clinical Trials & Observations
Amy K. Keating, Nathan Gossai, Christine L. Phillips, Kelly Maloney, Kristen Campbell, Andrew Doan, Deepa Bhojwani, Michael J. Burke, Michael R. Verneris
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1926–1929.
https://doi.org/10.1182/bloodadvances.2018025726
Published: 2019
Journal Articles

No free rides: management of toxicities of novel immunotherapies in ALL, including financial

Clinical Trials & Observations
Tania Jain, Mark R. Litzow
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3393–3403.
https://doi.org/10.1182/bloodadvances.2018020198
Published: 2018
Journal Articles

Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia

Clinical Trials & Observations
Anthony S. Stein, Richard A. Larson, Andre C. Schuh, William Stevenson, Ewa Lech-Maranda, Qui Tran, Zachary Zimmerman, William Kormany, Max S. Topp
Journal: Blood Advances
Blood Adv (2018) 2 (13): 1522–1531.
https://doi.org/10.1182/bloodadvances.2018019034
Published: 2018
Includes: Supplemental data
Journal Articles

Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL -rearranged infant ALL

Clinical Trials & Observations
Matthias Wölfl, Mareike Rasche, Matthias Eyrich, Renate Schmid, Dirk Reinhardt, Paul G. Schlegel
Journal: Blood Advances
Blood Adv (2018) 2 (12): 1382–1385.
https://doi.org/10.1182/bloodadvances.2018018093
Published: 2018
Journal Articles

Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies

Elias Jabbour, Hagop Kantarjian
Journal: Blood Advances
Blood Adv (2016) 1 (3): 260–264.
https://doi.org/10.1182/bloodadvances.2016000042
Published: 2016
Journal Articles

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Kara L. Davis, Crystal L. Mackall
Journal: Blood Advances
Blood Adv (2016) 1 (3): 265–269.
https://doi.org/10.1182/bloodadvances.2016000034
Published: 2016